bemethyl has been researched along with Erysipelas* in 2 studies
1 trial(s) available for bemethyl and Erysipelas
| Article | Year |
|---|---|
[Effectiveness of bemitil in recurrent erysipelas].
The trial entered 66 patients with recurrent erysipelas treated conventionally with addition of either immunostimulator bemitil (0.25-0.5 g/day orally for 5-7 days) or placebo. The bemitil group was free of intoxication symptoms and local manifestations, discharged from hospital sooner than the controls. Therapeutic efficacy of bemitil is due to its promotion of mononuclear phagocytes function which acts as an essential mechanism of antibacterial defence activation in patients with recurrent erysipelas. Topics: Adjuvants, Immunologic; Adult; Benzimidazoles; Combined Modality Therapy; Drug Administration Schedule; Erysipelas; Humans; Immune Tolerance; Middle Aged; Placebos; Recurrence; Ultraviolet Therapy | 1991 |
1 other study(ies) available for bemethyl and Erysipelas
| Article | Year |
|---|---|
[The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].
Bemitil, administered orally in a dose of 0.25-0.5 g a day for 5-7 days at the acute period of the relapse of erysipelas as an immunostimulant, enhanced the effectiveness of the basic therapy including antibiotics, anti-inflammatory and antiallergic drugs, vitamins, plasma-substituting fluids and saline solutions, as well as ultraviolet irradiation of the focus of lesion. Bemitil therapy was associated with an increase in the number of T-lymphocytes, normalization of the balance between the peripheral lymphocyte preparations, an increase of blood serum levels of IgA and IgM. Topics: Adjuvants, Immunologic; Antibody Formation; Benzimidazoles; Combined Modality Therapy; Drug Evaluation; Erysipelas; Humans; Immunity, Cellular; Length of Stay; Recurrence; Time Factors | 1991 |